UBE2K and acute myeloid leukemia: Corroborating a recent report [15], our study highlights that UBE2J2 and UBE2K are two important functional partners of MARCH5 in regulating apoptosis in AML cells and can serve as additional targets for enhancing venetoclax efficacy.